MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$212,384
Free Cash flow
$1,003,925
Unit: Dollar
Positive Cash Flow Breakdown
Deferred revenue
Net income (loss)
Accreted interest expense
Others
Negative Cash Flow Breakdown
Accounts receivable
Payment of contingent acquisitio...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Adjustment to contingent earnout liability
-
278,637
317,966
1,748,526
Net income (loss)
860,206
546,919
749,387
1,265,553
Depreciation and amortization
312,402
316,425
316,066
1,245,362
Stock options expense
90,556
90,556
58,706
205,457
Restricted common stock expense
158,052
122,893
153,776
1,518,104
Modification cost of accelerated vesting of restricted common stock
-
-
-
0
Accreted interest expense
843,129
-
-
-
Accounts receivable
1,940,306
-1,238,010
-292,053
341,434
Prepaid expenses and other current assets
185,101
-12,186
140,004
-63,296
Prepaid royalties
90,271
-38,283
79,513
-1,066,312
Accounts payable and accrued expenses
310,982
-1,194,631
158,728
-1,426,282
Deferred revenue
1,244,927
-65,221
-720,046
1,678,272
Net cash provided by operating activities
1,007,973
1,384,057
1,107,119
7,023,166
Purchase of property and equipment
4,048
7,022
17,539
19,261
Payment for acquisition, net of cash acquired-Resolute Innovation Inc
-
-
-
0
Payment for acquisition, net of cash acquired-Scite Inc.
-
-
-
0
Net cash used in investing activities
-4,048
-7,022
-17,539
-19,261
Proceeds from the exercise of stock options
0
157,500
-
180,800
Common stock repurchase
7,836
16,162
23,387
934,577
Payment of contingent acquisition consideration - scite and fiz
1,211,869
1,216,537
1,337,857
124,107
Net cash used in financing activities
-1,219,705
-1,075,199
-1,361,244
-877,884
Effect of exchange rate changes
3,396
5,181
115
1,260
Net increase (decrease) in cash and cash equivalents
-212,384
307,017
-271,549
6,127,281
Cash and cash equivalents, beginning of period
11,955,763
11,955,763
12,227,312
6,100,031
Cash and cash equivalents, end of period
12,050,396
12,262,780
11,955,763
12,227,312
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Deferred revenue
$1,244,927
Net income (loss)
$860,206
Accreted interest
expense
$843,129
Depreciation and
amortization
$312,402
Accounts payable and
accrued expenses
$310,982
Restricted common stock
expense
$158,052
Stock options expense
$90,556
Net cash provided by
operating activities
$1,007,973
Effect of exchange rate
changes
$3,396
Canceled cashflow
$2,812,281
Net increase
(decrease) in cash and cash...
-$212,384
Canceled cashflow
$1,011,369
Accounts receivable
$1,940,306
something is missing
-$596,603
Prepaid expenses and
other current assets
$185,101
Prepaid royalties
$90,271
Net cash used in
financing activities
-$1,219,705
Net cash used in
investing activities
-$4,048
Payment of contingent
acquisition consideration -...
$1,211,869
Common stock
repurchase
$7,836
Purchase of property and
equipment
$4,048
Buy us a coffee
Research Solutions, Inc. (RSSS)
Research Solutions, Inc. (RSSS)